Affiliation:
1. Institute of Life Sciences, Scuola Superiore Sant’Anna, Italy
2. University of Ferrara, Italy
3. Fondazione Toscana Gabriele Monasterio, Italy
Abstract
Abstract
Amyloidosis is a systemic disorder characterized by extracellular deposition of insoluble fibrils. The most common forms are amyloid light chain and amyloid transthyretin (ATTR) amyloidoses. Cardiac involvement may be found in both these forms, and is an important cause of morbidity and mortality. The clinical presentation of cardiac amyloidosis (CA) may be represented by congestive heart failure (HF), possibly progressing to end-stage HF, as well as atrial fibrillation with possible thromboembolic events, and also conduction disturbances related to amyloid infiltration of conduction fibres. Beyond therapies targeting the blood dyscrasia or the ATTR amyloidogenic cascade, a careful choice of drug therapies, need for device implantation, and possibly treatments for advanced HF is then warranted. In the present review, we try to provide a useful guide to clinicians treating patients with CA by enucleating 10 main questions and answering them based on the evidence available as well as expert opinion and our clinical experience.
Publisher
Oxford University Press (OUP)
Subject
Cardiology and Cardiovascular Medicine,Epidemiology
Reference31 articles.
1. The prevalence and management of systemic amyloidosis in western countries;Nienhuis;Kidney Dis (Basel),2016
2. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings;Vergaro;Eur J Prev Cardiol,2019
3. Red flags in cardiac amyloidosis;Kwok;Eur J Prev Cardiol,24
4. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis;Gillmore;Circulation,2016
5. Treatment of cardiac transthyretin amyloidosis: an update;Emdin;Eur Heart J,2019
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献